LIPA

Across TCGA pan-cancer cohorts, LIPA mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LIPA’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LIPA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LIPA is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where LIPA tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LIPA mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.874	<.001	11	view →
HNSC	All	IV	+0.665	<.001	11	view →
LUAD	Male	III,IV	−1.126	<.001	8	view →
LSCC	All	II,III,IV	−1.126	<.001	8	view →
PDAC	Female	II,III,IV	+1.038	<.001	6	view →
COAD	Female	II,III,IV	−0.321	.014	4	view →
OV	All	All	+0.688	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

LIPA–CCRCC

Open the CCRCC breakdown →